TABLE 3.
Treatment Response of the PP Cohort of Patients Having ≥PIPAC Treatments for Peritoneal Metastases of Colorectal Origin
| Parameter | PP Cohort (n = 104) | P | |
|---|---|---|---|
| Baseline | ≥3 PIPACs | ||
| RECIST (n = 59) | |||
| Partial response/stable | 35 (59.3%) | ||
| Progression | 24 (40.7%) | ||
| PRGS (n = 66) | |||
| 1–2 | 48 (72.7%) | ||
| 3–4 | 18 (27.3%) | ||
| Cytology (n = 49) | |||
| Positive | 27 (55.1%) | 15 (30.6%) | 0.006 |
| Negative | 22 (44.9%) | 34 (69.4%) | |
| ΔPCI (PIPAC1 vs 3) (n = 81) | |||
| ≥3 decrease | 24 (29.6%) | 0.503 | |
| <3 decrease or increase | 57 (70.4%) | ||
| Any symptoms (n = 104)ti | |||
| Yes | 56 (53.8%) | 48 (46.2%) | 0.267 |
| No | 48 (46.2%) | 56 (53.8%) | |
Surrogates for treatment response were available for a variable no. of patients as specified (n=). This number was used as denominator for the consecutive percentage calculation of outcomes.